恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者临床疗效分析.docVIP

恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者临床疗效分析 　　[摘要] 目的 通过观察恩替卡韦治疗失代偿期乙肝肝硬化的临床疗效，寻求更有效的失代偿期乙肝肝硬化的抗病毒治疗，从而改善其预后。 方法 收集我院感染科2013年4月～2014年3月门诊或住院的病例，根据2010年版《慢性乙型肝炎防治指南》，纳入符合初始抗病毒治疗指征的失代偿期乙肝肝硬化患者18例。对入组患者每3个月进行定期随访，完成生化学、病毒学及影像学相关检查。比较各病例用药期间各项评估指标，采用SPSS 13.0软件分析数据，评价用药效果。 结果 患者用药期间HBV-DNA、肝功能、凝血酶原活动度的检验指标治疗前后比较差异有统计学意义（P0.05）。 结论 恩替卡韦治疗失代偿期乙肝肝硬化临床特点是抗病毒能力强、安全性好，治疗效果非常显著。 　　[关键词] 恩替卡韦；失代偿期乙肝肝硬化；抗病毒治疗 　　[中图分类号] R512.62；R575.2 [文献标识码] B [文章编号] 1673-9701（2015）14-0071-03 　　[Abstract] Objective To seek more effective antiviral therapy for decompensated hepatitis B cirrhosis and improve the prognosis by observing the clinical efficacy of entecavir in treating decompensated hepatitis B cirrhosis. Methods All the outpatients and inpatients in department of infectious diseases of our hospital from April 2013 to March 2014 were chosen. According to the 2010 edition of Chronic hepatitis B prevention and treatment guidelines， 18 patients with decompensated hepatitis B cirrhosis in line with initial indications of antiviral therapy were included. The patients received regularly follow-up every 3 months， and related examinations of biochemistry， virology and imaging were completed. The evaluation indexes of patients during treatment were compared， the related data was analyzed by SPSS 13.0 software， and evaluated effects of drugs. Results The indicators including HBV-DNA， liver function and prothrombin activity of patients during treatment were compared， and the differences in comparing with indicators before and after treatment were statistically significant （P0.05）. Conclusion Entecavir in the treatment of decompensated hepatitis B cirrhosis is characterized by high antiviral ability， safety， and significant efficacy. 　　[Key words] Entecavir； Decompensated hepatitis B cirrhosis； Antiviral therapy 　　失代偿期乙肝肝硬化患者并发症多、病情重、预后较差。单纯的综合内科治疗并不能有效地控制患者病情的进展。而乙型肝炎病毒是导致肝组织持续受损并使病情进一步加重的根本原因，抑制病毒复制是控制病情进展的关键。近年来我院在综合治疗失代偿期乙型肝炎肝硬化的基础上，应用恩替卡韦抗病毒治疗，取得显著的疗效。恩替卡韦（ETV）是临床上一种新型的抗乙肝病毒治疗药物，具备能够迅速控制病毒复制的能力，且耐药性低[1